Developing More Efficacious Antidepressant Medications: Improving and Aligning Preclinical and Clinical Assessment Tools

Animal and Translational Models for CNS Drug Discovery

Volumn , Issue , 2008, Pages 165-197

  Cryan, John F ^a   Sánchez, Connie ^b   Dinan, Timothy G ^c   Borsini, Franco ^d  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b LUNDBECK RESEARCH USA   (United States)

^c University College Cork   (Ireland)

^d Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84884852241     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-373861-5.00007-2     Document Type: Chapter

References (212)

1. P. Andlin-Sobocki, B. Jonsson, H.U. Wittchen and J. Olesen (2005) Cost of disorders of the brain in Europe. Eur J Neurol 12(Suppl 1), 1-27.
2. C.J. Murray and A.D. Lopez (1997) Alternative projections of mortality and disability by cause 1990–2020: Global burden of disease study. Lancet 349(9064), 1498-1504.
3. J.F. Cryan and A. Holmes (2005) The ascent of mouse: Advances in modelling human depression and anxiety. Nat Rev Drug Discov 4(9), 775-790.
4. M.L. Wong and J. Licinio (2001) Research and treatment approaches to depression. Nat Rev Neurosci 2(5), 343-351.
5. M.L. Wong and J. Licinio (2004) From monoamines to genomic targets: A paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3(2), 136-151.
6. O. Berton and E.J. Nestler (2006) New approaches to antidepressant drug discovery: Beyond monoamines. Nat Rev Neurosci 7(2), 137-151.
7. M. Keller, S. Montgomery, W. Ball, M. Morrison, D. Snavely, G. Liu, et al. (2006) Lack of effi-cacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatr 59(3), 216-223.
8. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, J.J. Sramek, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281(5383), 1640-1645.
9. N.M. Rupniak and M.S. Kramer (1999) Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trend Pharmacol Sci 20(12), 485-490.
10. J.F. Cryan and D.A. Slattery (2007) Animal models of mood disorders: Recent developments. Curr Opin Psychiatr 20(1), 1-7.
11. J. Angst (1995) The epidemiology of depressive disorders. Eur Neuropsychopharmacol 5(Suppl), 95-98.
12. Y. Agid, G. Buzsaki, D.M. Diamond, R. Frackowiak, J. Giedd, J.A. Girault, et al. (2007) How can drug discovery for psychiatric disorders be improved? Nat Rev Drug Discov 6(3), 189-201.
13. M.N. Pangalos, L.E. Schechter and O. Hurko (2007) Drug development for CNS disorders: Strategies for balancing risk and reducing attrition. Nat Rev Drug Discov 6(7), 521-532.
14. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edition. American Psychiatric Press, Washington, DC.
15. R.C. Kessler, P. Berglund, O. Demler, R. Jin, D. Koretz, K.R. Merikangas, et al. (2003) The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 289(23), 3095-3105.
16. D.L. Evans, D.S. Charney, L. Lewis, R.N. Golden, J.M. Gorman, K.R. Krishnan, et al. (2005) Mood disorders in the medically ill: Scientific review and recommendations. Biol Psychiatr 58(3), 175-189.
17. E.A. Mayer, M. Craske and B.D. Naliboff (2001) Depression, anxiety, and the gastrointestinal system. J Clin Psychiatr 62(Suppl 8), 28-36. discussion 7
18. B.W. Penninx, A.T. Beekman, A. Honig, D.J. Deeg, R.A. Schoevers, J.T. van Eijk, et al. (2001) Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatr 58(3), 221-227.
19. A.J. Stunkard, M.S. Faith and K.C. Allison (2003) Depression and obesity. Biol Psychiatr 54(3), 330-337.
20. J. Licinio and M.L. Wong (2005) Depression, antidepressants and suicidality: A critical appraisal. Nat Rev Drug Discov 4(2), 165-171.
21. Connor, T.J. and Leonard, B.E. (2003). Biological markers of depression. In: Feighner, J.P., Preskorn, S.H., and Stanga, C.Y. (eds.), Handbook of Experimental Pharmacology, Antidepressants: Current and Future Perspectives, Springer-Verlag, Berlin.
22. E.J. Nestler and W.A. Carlezon Jr. (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatr 59(12), 1151-1159.
23. A. Wirz-Justice (2006) Biological rhythm disturbances in mood disorders. Int Clin Psychopharmacol 21(Suppl 1), S11-S15.
24. T.D. Wade, C.M. Bulik, M. Neale and K.S. Kendler (2000) Anorexia nervosa and major depression: Shared genetic and environmental risk factors. Am J Psychiatr 157(3), 469-471.
25. A.P. Moffoot, R.E. O’Carroll, J. Bennie, S. Carroll, H. Dick, K.P. Ebmeier, et al. (1994) Diurnal variation of mood and neuropsychological function in major depression with melancholia. J Affect Disord 32(4), 257-269.
26. K. Williams and M.F. Reynolds (2006) Sexual dysfunction in major depression. CNS Spectr 11(8 Suppl 9), 19-23.
27. G.W. Brown, M.N. Bhrolchain and T. Harris (1975) Social-class and psychiatric disturbance among women in an urban population. Sociology J Br Sociol Assoc 9(2), 225-254.
28. E.S. Paykel, T. Brugha and T. Fryers (2005) Size and burden of depressive disorders in Europe. Eur Neuropsychopharmacol 15(4), 411-423.
29. W. Rossler, H.J. Salize, J. van Os and A. Riecher-Rossler (2005) Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15(4), 399-409.
30. M.C. Blehar (2006) Women’s mental health research: The emergence of a biomedical field. Annu Rev Clin Psychol 2 135-160.
31. D.A. Slattery, A.L. Hudson and D.J. Nutt (2004) Invited review: The evolution of antide-pressant mechanisms. Fundam Clin Pharmacol 18(1), 1-21.
32. I.M. Anderson (2000) Selective serotonin reuptake inhibitors versus tricyclic antidepres-sants: A meta-analysis of efficacy and tolerability. J Affect Disord 58(1), 19-36.
33. P.J. Perry (1996) Pharmacotherapy for major depression with melancholic features: Relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 39(1), 1-6.
34. M. Hamilton (1970) A rating scale for depression. J Neurol Neurosurg Psychiatr 23 51-56.
35. S.A. Montgomery and M. Asberg (1979) A new depression scale designed to be sensitive to change. Br J Psychiatr 134 382-389.
36. P.R. Bieck and W.Z. Potter (2005) Biomarkers in psychotropic drug development: Integration of data across multiple domains. Annu Rev Pharmacol Toxicol 45 227-246.
37. G.J. Downing (2002) Enhancing pathways to therapeutic development with clinical biomarkers. Am J Geriatr Psychiatr 10(6), 646-648.
38. M. Fava (2003) Diagnosis and definition of treatment-resistant depression. Biol Psychiatr 53(8), 649-659.
39. B.J. Carroll (1982) The dexamethasone suppression test for melancholia. Br J Psychiatr 140 292-304.
40. F. Holsboer, W. Bender, O. Benkert, H.E. Klein and M. Schmauss (1980) Diagnostic value of dexamethasone suppression test in depression. Lancet 2(8196), 706.
41. A.J. Rush, D.E. Giles, M.A. Schlesser, P.J. Orsulak, C.R. Parker Jr., J.E. Weissenburger, et al. (1996) The dexamethasone suppression test in patients with mood disorders. J Clin Psychiatr 57(10), 470-484.
42. H. Anisman and R.M. Zacharko (1990) Multiple neurochemical and behavioral consequences of stressors: Implications for depression. Pharmacol Ther 46(1), 119-136.
43. N. Barden (2004) Implication of the hypothalamic–pituitary–adrenal axis in the physiopa-thology of depression. J Psychiatr Neurosci 29(3), 185-193.
44. D.S. Charney and H.K. Manji (2004) Life stress genes, and depression: Multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE 2004(225), re5.
45. E.R. de Kloet, M. Joels and F. Holsboer (2005) Stress and the brain: from adaptation to disease. Nat Rev Neurosci 6(6), 463-475.
46. T.G. Dinan (1994) Glucocorticoids and the genesis of depressive illness. A psychobiological model. Br J Psychiatr 164(3), 365-371.
47. R.S. Duman (2004) Depression: A case of neuronal life and death? Biol Psychiatr 56(3), 140-145.
48. E.J. Nestler, M. Barrot, R.J. DiLeone, A.J. Eisch, S.J. Gold and L.M. Monteggia (2002) Neurobiology of depression. Neuron 34(1), 13-25.
49. F. Holsboer (2000) The corticosteroid receptor hypothesis of depression. Neuropsycho-pharmacology 23(5), 477-501.
50. C.M. Pariante and A.H. Miller (2001) Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatr 49(5), 391-404.
51. T. Steckler, F. Holsboer and J.M. Reul (1999) Glucocorticoids and depression. Baillieres Best Pract Res Clin Endocrinol Metab 13(4), 597-614.
52. W. Vale, J. Spiess, C. Rivier and J. Rivier (1981) Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213(4514), 1394-1397.
53. V. Duvigneaud, D.T. Gish and P.G. Katsoyannis (1954) A synthetic preparation possessing biological properties associated with arginine–vasopressin. J Am Chem Soc 76(18), 4751-4752.
54. L.V. Scott and T.G. Dinan (1998) Vasopressin and the regulation of hypothalamic–pituitary–adrenal axis function: Implications for the pathophysiology of depression. Life Sci 62(22), 1985-1998.
55. P.H. Baylis (1989) Regulation of vasopressin secretion. Baillieres Clin Endocrinol Metab 3(2), 313-330.
56. M.J. McKinley, M.L. Mathai, R.M. McAllen, R.C. McClear, R.R. Miselis, G.L. Pennington, et al. (2004) Vasopressin secretion: Osmotic and hormonal regulation by the lamina terminalis. J Neuroendocrinol 16(4), 340-347.
57. D. Murphy, S. Waller, K. Fairhall, D.A. Carter and I.C.A.F. Robinson (1998) Regulation of the synthesis and secretion of vasopressin. Adv Brain Vasopressin 119 137-143.
58. D. deWied (1997) Neuropeptides in learning and memory processes. Behav Brain Res 83(1–2), 83-90.
59. M.H. Whitnall, D. Smyth and H. Gainer (1987) Vasopressin coexists in 1/2 of the corticotropin-releasing factor axons present in the external zone of the median-eminence in normal rats. Neuroendocrinology 45(5), 420-424.
60. L.V. Scott and T.G. Dinan (2002) Vasopressin as a target for antidepressant development: An assessment of the available evidence. J Affect Disord 72(2), 113-124.
61. E.R. De Kloet, E. Vreugdenhil, M.S. Oitzl and M. Joels (1998) Brain corticosteroid receptor balance in health and disease. Endocr Rev 19(3), 269-301.
62. X.M. Ma, S.L. Lightman and G. Aguilera (1999) Vasopressin and corticotropin-releasing hormone gene responses to novel stress in rats adapted to repeated restraint. Endocrinology 140(8), 3623-3632.
63. P.W. Gold, F.K. Goodwin and V.I. Reus (1978) Vasopressin in affective-illness. Lancet 1(8076), 1233-1236.
64. M.A. Cole, P.J. Kim, B.A. Kalman and R.L. Spencer (2000) Dexamethasone suppression of corticosteroid secretion: Evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 25(2), 151-167.
65. U. Vonbardeleben and F. Holsboer (1989) Cortisol response to a combined dexamethasone human corticotropin-releasing hormone challenge in patients with depression. J Neuroendocrinol 1(6), 485-488.
66. I. Heuser, A. Yassouridis and F. Holsboer (1994) The combined dexamethasone CRH test – A refined laboratory test for psychiatric-disorders. J Psychiatr Res 28(4), 341-356.
67. A. Gjerris, M. Hammer, P. Vendsborg, N.J. Christensen and O.J. Rafaelsen (1985) Cerebrospinal-fluid vasopressin – Changes in depression. Br J Psychiatr 147 696-701.
68. L. vanLonden, J.G. Goekoop, G.M.J. vanKempen, A.C. FrankhuijzenSierevogel, V.M. Wiegant, E.A. vanderVelde, et al. (1997) Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 17(4), 284-292.
69. W.J. Inder, R.A. Donald, T.C.R. Prickett, C.M. Frampton, P.F. Sullivan, R.T. Mulder, et al. (1997) Arginine vasopressin is associated with hypercortisolemia and suicide attempts in depression. Biological Psychiatr 42(8), 744-747.
70. J.S. Purba, W.J.G. Hoogendijk, M.A. Hofman and D.F. Swaab (1996) Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypo-thalamus in depression. Arch Gen Psychiatr 53(2), 137-143.
71. F.C. Raadsheer, W.J.G. Hoogendijk, F.C. Stam, F.J.H. Tilders and D.F. Swaab (1994) Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic para-ventricular nucleus of depressed-patients. Neuroendocrinology 60(4), 436-444.
72. T.G. Dinan, E. Lavelle, L.V. Scott, J. Newell-Price, S. Medbak and A.B. Grossman (1999) Desmopressin normalizes the blunted adrenocorticotropin response to corticotropin-releasing hormone in melancholic depression: Evidence of enhanced vasopressinergic responsivity. J Clin Endocrinol Metab 84(6), 2238-2240.
73. M.B. Muller, R. Landgraf, J. Preil, I. Sillaber, A.E. Kresse, M.E. Keck, et al. (2000) Selective activation of the hypothalamic vasopressinelgic system in mice deficient for the cortico-tropin-releasing hormone receptor 1 is dependent on glucocorticoids. Endocrinology 141(11), 4262-4269.
74. M.D. Debellis, P.W. Gold, T.D. Geracioti, S.J. Listwak and M.A. Kling (1993) Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am J Psychiatr 150(4), 656-657.
75. I. Heuser, G. Bissette, M. Dettling, U. Schweiger, U. Gotthardt, J. Schmider, et al. (1998) Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: Response to amitriptyline treatment. Depress Anxiety 8(2), 71-79.
76. D. van West, J. Del-Favero, Y. Aulchenko, P. Oswald, D. Souery, T. Forsgren, et al. (2004) A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression. Mol Psychiatr 9(3), 287-292.
77. E.L. Dempster, I. Burcescu, K. Wigg, E. Kiss, I. Baji, J. Gadoros, et al. (2007) Evidence of an association between the vasopressin V1b receptor gene (AVPR1B) and childhood-onset mood disorders. Arch Gen Psychiatr 64(10), 1189-1195.
78. G. Griebel, J. Stemmelin, C.S.L. Gal and P. Soubrie (2005) Non-peptide vasopressin V-1b receptor antagonists as potential drugs for the treatment of stress-related disorders. Curr Pharmaceut Des 11(12), 1549-1559.
79. D.M. Nielsen (2006) Corticotropin-releasing factor type-1 receptor antagonists: The next class of antidepressants? Life Sci 78(9), 909-919.
80. B.H. Flores, H. Kenna, J. Keller, H.B. Solvason and A.F. Schatzberg (2006) Clinical and biological effects of mifepristone treatment for psychotic depression. Neuropsychopharmacology 31(3), 628-636.
81. D.G. Healy, A. Harkin, J.F. Cryan, J.P. Kelly and B.E. Leonard (1999) Metyrapone displays antidepressant-like properties in preclinical paradigms. Psychopharmacology (Berl) 145(3), 303-308.
82. J.H. Thakore and T.G. Dinan (1995) Cortisol synthesis inhibition – A new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatr 37(6), 346-348.
83. G.W. Arana, A.B. Santos, M.T. Laraia, S. Mcleodbryant, M.D. Beale, L.J. Rames, et al. (1995) Dexamethasone for the treatment of depression – A randomized placebo-controlled, double-blind trial. Am J Psychiatr 152(2), 265-267.
84. J.A. DiMasi, R.W. Hansen and H.G. Grabowski (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22(2), 151-185.
85. S. Frantz (2004) Therapeutic area influences drug development costs. Nat Rev Drug Discov 3(6), 466-467.
86. A. Lakoff (2002) The mousetrap: Managing the placebo effect in antidepressant trials. Mol Interv 2(2), 72-76.
87. R. McArthur and F. Borsini (2006) Animal models of depression in drug discovery: A historical perspective. Pharmacol Biochem Behav 84(3), 436-452.
88. J.F. Cryan, A. Markou and I. Lucki (2002) Assessing antidepressant activity in rodents: Recent developments and future needs. Trend Pharmacol Sci 23(5), 238-245.
89. J.F. Cryan and C. Mombereau (2004) In search of a depressed mouse: Utility of models for studying depression-related behavior in genetically modified mice. Mol Psychiatr 9(4), 326-357.
90. N.M. Rupniak (2003) Animal models of depression: Challenges from a drug development perspective. Behav Pharmacol 14(5–6), 385-390.
91. S. Chaki, A. Nakazato, L. Kennis, M. Nakamura, C. Mackie, M. Sugiura, et al. (2004) Anxiolytic- and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur J Pharmacol 485(1–3), 145-158.
92. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, N. Kawashima, et al. (2004) MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46(4), 457-467.
93. J.F. Cryan and K. Kaupmann (2005) Don’t worry ‘B’ happy!: A role for GABA(B) receptors in anxiety and depression. Trend Pharmacol Sci 26(1), 36-43.
94. C.J. Swanson, M. Bures, M.P. Johnson, A.M. Linden, J.A. Monn and D.D. Schoepp (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4(2), 131-144.
95. M.A. Geyer and A. Markou (1995) Animal models of psychiatric disorders. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: The Fourth Generation of Progress Raven Press 787-798.
96. J.C. Crabbe, D. Wahlsten and B.C. Dudek (1999) Genetics of mouse behavior: Interactions with laboratory environment. Science 284(5420), 1670-1672.
97. D. Wahlsten, P. Metten, T.J. Phillips, S.L. Boehm II, S. Burkhart-Kasch, J. Dorow, et al. (2003) Different data from different labs: Lessons from studies of gene–environment interaction. J Neurobiol 54(1), 283-311.
98. I. Lucki (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8(6–7), 523-532.
99. F. Borsini, K. Evans, K. Jason, F. Rohde, B. Alexander and S. Pollentier (2002) Pharmacology of flibanserin. CNS Drug Rev 8(2), 117-142.
100. S.A. Montgomery, H. Loft, C. Sanchez, E.H. Reines and M. Papp (2001) Escitalopram (S-enantiomer of citalopram): Clinical efficacy and onset of action predicted from a rat model. Pharmacol Toxicol 88(5), 282-286.
101. C. Sanchez (2006) The pharmacology of citalopram enantiomers: The antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol 99(2), 91-95.
102. I.I. Gottesman and T.D. Gould (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatr 160(4), 636-645.
103. G. Hasler, W.C. Drevets, T.D. Gould, I.I. Gottesman and H.K. Manji (2006) Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatr 60(2), 93-105.
104. G. Hasler, W.C. Drevets, H.K. Manji and D.S. Charney (2004) Discovering endophenotypes for major depression. Neuropsychopharmacology 29(10), 1765-1781.
105. S.E. Hyman and W.S. Fenton (2003) Medicine. What are the right targets for psychopharmacology? Science 299(5605), 350-351.
106. I.I. Gottesman and J. Shields (1973) Genetic theorizing and schizophrenia. Br J Psychiatr 122(566), 15-30.
107. T.D. Gould and I.I. Gottesman (2006) Psychiatric endophenotypes and the development of valid animal models. Gene Brain Behav 5(2), 113-119.
108. K. Matthews, D. Christmas, J. Swan and E. Sorrell (2005) Animal models of depression: Navigating through the clinical fog. Neurosci Biobehav Rev 29(4–5), 503-513.
109. M.A. Geyer and A. Markou (2002) The role of preclinical models in the development of psychotropic drugs. F.E. Bloom, D.J. Kupfer (Eds) Psychopharmacology: The Fifth Generation of Progress New York: Raven
110. D.A. Pizzagalli, A.L. Jahn and J.P. O’Shea (2005) Toward an objective characterization of an anhedonic phenotype: A signal-detection approach. Biol Psychiatr 57(4), 319-327.
111. A.Y. Shestyuk, P.J. Deldin, J.E. Brand and C.M. Deveney (2005) Reduced sustained brain activity during processing of positive emotional stimuli in major depression. Biol Psychiatr 57(10), 1089-1096.
112. R. Elliott (1998) The neuropsychological profile in unipolar depression. Trend Cogn Sci 2(11), 447-454.
113. J.R. Hollerman, L. Tremblay and W. Schultz (2000) Involvement of basal ganglia and orbitofrontal cortex in goal-directed behavior. Prog Brain Res 126 193-215.
114. M.L. Kringelbach (2005) The human orbitofrontal cortex: Linking reward to hedonic experience. Nat Rev Neurosci 6(9), 691-702.
115. J. Olds and P. Milner (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol Psychol 47(6), 419-427.
116. C. Kornetsky (2004) Brain-stimulation reward, morphine-induced oral stereotypy, and sensitization: Implications for abuse. Neurosci Biobehav Rev 27(8), 777-786.
117. A. Markou and G.F. Koob (1992) Construct validity of a self-stimulation threshold paradigm: Effects of reward and performance manipulations. Physiol Behav 51(1), 111-119.
118. A.G. Phillips, C.D. Blaha and H.C. Fibiger (1989) Neurochemical correlates of brain-stimulation reward measured by ex vivo and in vivo analyses. Neurosci Biobehav Rev 13(2–3), 99-104.
119. R.A. Wise, P. Bauco, W.A. Carlezon Jr. and W. Trojniar (1992) Self-stimulation and drug reward mechanisms. Ann N Y Acad Sci 654 192-198.
120. J.L. Moreau, F. Jenck, J.R. Martin, P. Mortas and W.E. Haefely (1992) Antidepressant treatment prevents chronic unpredictable mild stress-induced anhedonia as assessed by ventral tegmentum self-stimulation behavior in rats. Eur Neuropsychopharmacol 2(1), 43-49.
121. J.F. Cryan, D. Hoyer and A. Markou (2003) Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatr 54(1), 49-58.
122. L.K. Tremblay, C.A. Naranjo, S.J. Graham, N. Herrmann, H.S. Mayberg, S. Hevenor, et al. (2005) Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe. Arch Gen Psychiatr 62(11), 1228-1236.
123. L.K. Tremblay, C.A. Naranjo, L. Cardenas, N. Herrmann and U.E. Busto (2002) Probing brain reward system function in major depressive disorder: Altered response to dextroamphetamine. Arch Gen Psychiatr 59(5), 409-416.
124. C.A. Naranjo, L.K. Tremblay and U.E. Busto (2001) The role of the brain reward system in depression. Prog Neuropsychopharmacol Biol Psychiatr 25(4), 781-823.
125. B. Crespo-Facorro, S. Paradiso, N.C. Andreasen, D.S. O’Leary, G.L. Watkins, L.L. Ponto, et al. (2001) Neural mechanisms of anhedonia in schizophrenia: A PET study of response to unpleasant and pleasant odors. JAMA 286(4), 427-435.
126. M.A. Rogers, K. Kasai, M. Koji, R. Fukuda, A. Iwanami, K. Nakagome, et al. (2004) Executive and prefrontal dysfunction in unipolar depression: A review of neuropsychological and imaging evidence. Neurosci Res 50(1), 1-11.
127. M.L. Phillips, W.C. Drevets, S.L. Rauch and R. Lane (2003) Neurobiology of emotion perception II: Implications for major psychiatric disorders. Biol Psychiatr 54(5), 515-528.
128. J.W. Dalley, R.N. Cardinal and T.W. Robbins (2004) Prefrontal executive and cognitive functions in rodents: Neural and neurochemical substrates. Neurosci Biobehav Rev 28(7), 771-784.
129. J.D. Bremner, M. Narayan, E.R. Anderson, L.H. Staib, H.L. Miller and D.S. Charney (2000) Hippocampal volume reduction in major depression. Am J Psychiatr 157(1), 115-118.
130. S. Campbell, M. Marriott, C. Nahmias and G.M. MacQueen (2004) Lower hippocampal volume in patients suffering from depression: A meta-analysis. Am J Psychiatr 161(4), 598-607.
131. G.M. MacQueen, S. Campbell, B.S. McEwen, K. Macdonald, S. Amano, R.T. Joffe, et al. (2003) Course of illness, hippocampal function, and hippocampal volume in major depression. Proc Natl Acad Sci USA 100(3), 1387-1392.
132. I.M. Rosso (2005) Review: Hippocampal volume is reduced in people with unipolar depression. Evid Based Ment Health 8(2), 45.
133. Y.I. Sheline, M.H. Gado and H.C. Kraemer (2003) Untreated depression and hippocampal volume loss. Am J Psychiatr 160(8), 1516-1518.
134. Y.I. Sheline, M. Sanghavi, M.A. Mintun and M.H. Gado (1999) Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 19(12), 5034-5043.
135. E.S. Brown, A.J. Rush and B.S. McEwen (1999) Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders. Neuropsychopharmacology 21(4), 474-484.
136. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, et al. (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301(5634), 805-809.
137. H.D. Schmidt and R.S. Duman (2007) The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. Behav Pharmacol 18(5–6), 391-418.
138. E.A. Nofzinger, R.M. Schwartz, C.F. Reynolds III, M.E. Thase, J.R. Jennings, E. Frank, et al. (1993) Correlation of nocturnal penile tumescence and daytime affect intensity in depressed men. Psychiatr Res 49(2), 139-150.
139. C.A. McClung (2007) Circadian genes, rhythms and the biology of mood disorders. Pharmacol Ther 114(2), 222-232.
140. R.W. Lam (2006) Sleep disturbances and depression: A challenge for antidepressants. Int Clin Psychopharmacol 21(Suppl 1), S25-S29.
141. S. Wilson and S. Argyropoulos (2005) Antidepressants and sleep: A qualitative review of the literature. Drugs 65(7), 927-947.
142. A. Ghosh and J.S. Hellewell (2007) A review of the efficacy and tolerability of agomelatine in the treatment of major depression. Expert Opin Investig Drug 16(12), 1999-2004.
143. M. Banasr, A. Soumier, M. Hery, E. Mocaer and A. Daszuta (2006) Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatr 59(11), 1087-1096.
144. N. Barden, E. Shink, M. Labbe, R. Vacher, J. Rochford and E. Mocaer (2005) Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog Neuropsychopharmacol Biol Psychiatr 29(6), 908-916.
145. V. Bertaina-Anglade, C.D. la Rochelle, P.A. Boyer and E. Mocaer (2006) Antidepressant-like effects of agomelatine (S 20098) in the learned helplessness model. Behav Pharmacol 17(8), 703-713.
146. F. Loiseau, C. Le Bihan, M. Hamon and M.H. Thiebot (2005) Antidepressant-like effects of agomelatine, melatonin and the NK1 receptor antagonist GR205171 in impulsive-related behaviour in rats. Psychopharmacology (Berl) 182(1), 24-32.
147. M. Zupancic and C. Guilleminault (2006) Agomelatine: A preliminary review of a new antidepressant. CNS Drug 20(12), 981-992.
148. B. Conti, R. Maier, A.M. Barr, M.C. Morale, X. Lu, P.P. Sanna, et al. (2007) Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol Psychiatr 12(2), 167-189.
149. J.C. Wu and W.E. Bunney (1990) The biological basis of an antidepressant response to sleep deprivation and relapse: Review and hypothesis. Am J Psychiatr 147(1), 14-21.
150. P. Moore, C. Gillin, T. Bhatti, A. DeModena, E. Seifritz, C. Clark, et al. (1998) Rapid tryptophan depletion, sleep electroencephalogram, and mood in men with remitted depression on serotonin reuptake inhibitors. Arch Gen Psychiatr 55(6), 534-539.
151. J.C. Gillin, W. Jernajczyk, D.C. Valladares-Neto, S. Golshan, M. Lardon and S.M. Stahl (1994) Inhibition of REM sleep by ipsapirone, a 5HT1A agonist, in normal volunteers. Psychopharmacology (Berl) 116(4), 433-436.
152. C. Monaca, B. Boutrel, R. Hen, M. Hamon and J. Adrien (2003) 5-HT 1A/1B receptor-mediated effects of the selective serotonin reuptake inhibitor, citalopram, on sleep: Studies in 5-HT 1A and 5-HT 1B knockout mice. Neuropsychopharmacology 28(5), 850-856.
153. M. El Yacoubi, S. Bouali, D. Popa, L. Naudon, I. Leroux-Nicollet, M. Hamon, et al. (2003) Behavioral, neurochemical, and electrophysiological characterization of a genetic mouse model of depression. Proc Natl Acad Sci USA 100(10), 6227-6232.
154. A. Germain, E.A. Nofzinger, D.J. Kupfer and D.J. Buysse (2004) Neurobiology of non-REM sleep in depression: Further evidence for hypofrontality and thalamic dysregulation. Am J Psychiatr 161(10), 1856-1863.
155. I. Antonijevic (2007) HPA axis and sleep: Identifying subtypes of major depression. Stress 11(1), 15-27.
156. M. Bucan and T. Abel (2002) The mouse: Genetics meets behaviour. Nat Rev Genet 3(2), 114-123.
157. L.H. Tecott (2003) The genes and brains of mice and men. Am J Psychiatr 160(4), 646-656.
158. T.J. Phillips, J.K. Belknap, R.J. Hitzemann, K.J. Buck, C.L. Cunningham and J.C. Crabbe (2001) Harnessing the mouse to unravel the genetics of human disease. Gene Brain Behav 1(1), 14-26.
159. R. Gerlai (2001) Gene targeting: Technical confounds and potential solutions in behavioral brain research. Behav Brain Res 125(1–2), 13-21.
160. D. Pfaff (2001) Precision in mouse behavior genetics. Proc Natl Acad Sci USA 98(11), 5957-5960.
161. J.F. Cryan, D.R. Thakker and D. Hoyer (2007) Emerging use of non-viral RNA interference in the brain. Biochem Soc Trans 35(Pt 2), 411-415.
162. M. Fendt, S. Schmid, D.R. Thakker, L.H. Jacobson, R. Yamamoto, K. Mitsukawa, et al. (2007) mGluR7 facilitates extinction of aversive memories and controls amygdala plasticity. Mol Psychiatr
163. D.R. Thakker, D. Hoyer and J.F. Cryan (2006) Interfering with the brain: Use of RNA interference for understanding the pathophysiology of psychiatric and neurological disorders. Pharmacol Ther 109(3), 413-438.
164. D.R. Thakker, F. Natt, D. Husken, R. Maier, M. Muller, H. van der Putten, et al. (2004) Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci USA 101(49), 17270-17275.
165. D.R. Thakker, F. Natt, D. Husken, H. van der Putten, R. Maier, D. Hoyer, et al. (2005) siRNA-mediated knockdown of the serotonin transporter in the adult mouse brain. Mol Psychiatr 10(8), 782-789.
166. J.N. Crawley (2000) What’s Wrong with My Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice. New York: Wiley-Liss
167. R. Landgraf, M.S. Kessler, M. Bunck, C. Murgatroyd, D. Spengler, M. Zimbelmann, et al. (2007) Candidate genes of anxiety-related behavior in HAB/LAB rats and mice: Focus on vasopressin and glyoxalase-I. Neurosci Biobehav Rev 31(1), 89-102.
168. P. Muigg, U. Hoelzl, K. Palfrader, I. Neumann, A. Wigger, R. Landgraf, et al. (2007) Altered brain activation pattern associated with drug-induced attenuation of enhanced depression-like behavior in rats bred for high anxiety. Biol Psychiatr 61(6), 782-796.
169. I.D. Neumann, A. Wigger, S. Kromer, E. Frank, R. Landgraf and O.J. Bosch (2005) Differential effects of periodic maternal separation on adult stress coping in a rat model of extremes in trait anxiety. Neuroscience 132(3), 867-877.
170. D.H. Overstreet, E. Friedman, A.A. Mathe and G. Yadid (2005) The Flinders Sensitive Line rat: A selectively bred putative animal model of depression. Neurosci Biobehav Rev 29(4–5), 739-759.
171. V. Krishnan, M.H. Han, D.L. Graham, O. Berton, W. Renthal, S.J. Russo, et al. (2007) Molecular adaptations underlying susceptibility and resistance to social defeat in brain reward regions. Cell 131(2), 391-404.
172. M.A. Fox, A.M. Andrews, J.R. Wendland, K.P. Lesch, A. Holmes and D.L. Murphy (2007) A pharmacological analysis of mice with a targeted disruption of the serotonin transporter. Psychopharmacology (Berl) 195(2), 147-166.
173. A.R. Hariri and A. Holmes (2006) Genetics of emotional regulation: The role of the serotonin transporter in neural function. Trend Cogn Sci 10(4), 182-191.
174. L. Gray and A.J. Hannan (2007) Dissecting cause and effect in the pathogenesis of psychiatric disorders: Genes, environment and behaviour. Curr Mol Med 7(5), 470-478.
175. T.E. Moffitt, A. Caspi and M. Rutter (2005) Strategy for investigating interactions between measured genes and measured environments. Arch Gen Psychiatr 62(5), 473-481.
176. J.C. Crabbe and R.G. Morris (2004) Festina lente: Late-night thoughts on high-throughput screening of mouse behavior. Nat Neurosci 7(11), 1175-1179.
177. L.H. Tecott and E.J. Nestler (2004) Neurobehavioral assessment in the information age. Nat Neurosci 7(5), 462-466.
178. T.W. Robbins (1998) Homology in behavioural pharmacology: An approach to animal models of human cognition. Behav Pharmacol 9(7), 509-519.
179. P.A. Cannistraro and S.L. Rauch (2003) Neural circuitry of anxiety: Evidence from structural and functional neuroimaging studies. Psychopharmacol Bull 37(4), 8-25.
180. H.S. Mayberg, A.M. Lozano, V. Voon, H.E. McNeely, D. Seminowicz, C. Hamani, et al. (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45(5), 651-660.
181. S. Bissiere, K.H. McAllister, H.R. Olpe and J.F. Cryan (2006) The rostral anterior cingulate cortex modulates depression but not anxiety-related behaviour in the rat. Behav Brain Res 175(1), 195-199.
182. Bissiere, S., Plachta, N., Hoyer, D., McAllister, K.H., Olpe, H.R., Grace, A. et al. (2008). The rostral anterior cingulate cortex modulates the efficiency of amygdala-dependent fear learning, Biol Psychiatr, 63(9):821–831.
183. Slattery, D.A. and Cryan. J.F. (2008). The infralimbic cortex modulates stress-induced coping behaviour in the rat. Frontiers Behav Neurosci (in press).
184. M. Rudin and R. Weissleder (2003) Molecular imaging in drug discovery and development. Nat Rev Drug Discov 2(2), 123-131.
185. R.D. Airan, L.A. Meltzer, M. Roy, Y.Q. Gong, H. Chen and K. Deisseroth (2007) High-speed imaging reveals neurophysiological links to behavior in an animal model of depression. Science 317(5839), 819-823.
186. S.E. Hyman (2007) Can neuroscience be integrated into the DSM-V? Nat Rev Neurosci 8(9), 725-732.
187. L.E. Schechter, R.H. Ring, C.E. Beyer, Z.A. Hughes, X. Khawaja, J.E. Malberg, et al. (2005) Innovative approaches for the development of antidepressant drugs: Current and future strategies. NeuroRx 2(4), 590-611.
188. B. Petit-Demouliere, F. Chenu and M. Bourin (2005) Forced swimming test in mice: A review of antidepressant activity. Psychopharmacology (Berl) 177(3), 245-255.
189. F. Borsini (1995) Role of the serotonergic system in the forced swimming test. Neurosci Biobehav Rev 19(3), 377-395.
190. J.F. Cryan, R.J. Valentino and I. Lucki (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci Biobehav Rev 29(4–5), 547-569.
191. J.F. Cryan, C. Mombereau and A. Vassout (2005) The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29(4–5), 571-625.
192. A. Harkin, J.P. Kelly and B.E. Leonard (2003) A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clin Neurosci Res 3 253-262.
193. J.P. Kelly, A.S. Wrynn and B.E. Leonard (1997) The olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 74(3), 299-316.
194. C. Song and B.E. Leonard (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29(4–5), 627-647.
195. J.M. O’Donnell, G.J. Marek and L.S. Seiden (2005) Antidepressant effects assessed using behavior maintained under a differential-reinforcement-of-low-rate (DRL) operant schedule. Neurosci Biobehav Rev 29(4–5), 785-798.
196. C.R. Pryce, D. Ruedi-Bettschen, A.C. Dettling, A. Weston, H. Russig, B. Ferger, et al. (2005) Long-term effects of early-life environmental manipulations in rodents and primates: Potential animal models in depression research. Neurosci Biobehav Rev 29(4–5), 649-674.
197. C.R. Pryce and J. Feldon (2003) Long-term neurobehavioural impact of the postnatal environment in rats: Manipulations, effects and mediating mechanisms. Neurosci Biobehav Rev 27(1–2), 57-71.
198. C.R. Pryce, D. Ruedi-Bettschen, A.C. Dettling and J. Feldon (2002) Early life stress: Long-term physiological impact in rodents and primates. News Physiol Sci 17 150-155.
199. G. Vogel, D. Neill, D. Kors and M. Hagler (1990) REM sleep abnormalities in a new animal model of endogenous depression. Neurosci Biobehav Rev 14(1), 77-83.
200. E. Fuchs (2005) Social stress in tree shrews as an animal model of depression: An example of a behavioral model of a CNS disorder. CNS Spectr 10(3), 182-190.
201. C. Ducottet, G. Griebel and C. Belzung (2003) Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Prog Neuropsychopharmacol Biol Psychiatr 27(4), 625-631.
202. P. Willner (1997) Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology (Berl) 134(4), 319-329.
203. P. Willner, R. Muscat and M. Papp (1992) Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neurosci Biobehav Rev 16(4), 525-534.
204. P.J. Mitchell (2005) Antidepressant treatment and rodent aggressive behaviour. Eur J Pharmacol 526(1–3), 147-162.
205. B.R. Cooper, T.J. Hester and R.A. Maxwell (1980) Behavioral and biochemical effects of antidepressant bupropion (Wellbutin): Evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215(1), 127-134.
206. J.H. Meyer, V.S. Goulding, A.A. Wilson, D. Hussey, B.K. Christensen and S. Houle (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163(1), 102-105.
207. De Vivo and Maayani (1986). Characterization of the 5-hydroxytryptamine1a receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes. J Pharmacol Exp Ther, 238(1):248–253.
208. D. Marazziti, L. Palego, A. Giromella, M.R. Mazzoni, F. Borsini, N. Mayer, A.G. Naccarato, A. Lucacchini and G.B. Cassano (2002) Region-dependent effects of flibanserin and buspirone in adenylyl cyclase activity in the human brain. Int J Neuropsychopharmacol 5(2), 131-140.
209. E.A. Rabiner, R.N. Gunn, M.R. Wilkins, P.A. Sargent, E. Mocaer, W. Sedman, P.J. Cowen and P.M. Grasby (2000) Drug action at 5-HT(1A) receptor in vivo: Autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl-(11C)]WAY-100635. Nucl Med Biol 27(5), 509-513.
210. F. Artigas, V. Perez and E. Alvarez (1994) Pindolol induces a rapid improvement of depressed patients with serotonin reuptake inhibitors. Arch Gen Psychiatr 51(3), 248-251.
211. T.I. Cremers, L.J. Wiersma, F.J. Bosker, J.A. den Boer, B.H. Westrink and H.V. Wikstrom (2001) Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism? Biol Psychiatr 50(1), 13-21.
212. E.A. Rabiner, Z. Bhagwagar, R.N. Gunn, P.A. Sargent, C.J. Bench, P.J. Cowen and P.M. Grasby (2001) Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am J Psychiatr 158(12), 2080-2082.